Loading…
for educational and safety purposes
3-HO-PCP and 3-HO-PCE both come up in the same conversations; they overlap on Glutamate and Opioid receptors. 3-HO-PCP: 3-HO-PCP (3-hydroxyphencyclidine) is a hydroxylated analog of phencyclidine that acts as an NMDA receptor antagonist and, unusually for a dissociative, also displays notable mu-opioid receptor activity arising from its 3-hydroxy group; it is reported to be more potent than PCP itself. 3-HO-PCE: 3-HO-PCE (3-hydroxyeticyclidine) is an arylcyclohexylamine of the eticyclidine (PCE) family that produces dissociative, hallucinogenic, and euphoric effects and is presumed to act as an NMDA receptor antagonist.
3-HO-PCP (3-hydroxyphencyclidine) is a hydroxylated analog of phencyclidine that acts as an NMDA receptor antagonist and, unusually for a dissociative, also displays notable mu-opioid receptor activity arising from its 3-hydroxy group; it is reported to be more potent than PCP itself. This dual mechanism can add opioid-like sedation and respiratory risk to the expected dissociative effects. Analytically confirmed case reports document severe toxicity, including hyperthermia, tachycardia, rhabdomyolysis, and serotonergic features, and forensic studies have quantified the drug and mapped its hepatic metabolism, noting brain concentrations exceeding those in blood. In silico work flags moderate acute toxicity and potential cardiotoxicity, while controlled human data remain absent.
3-HO-PCE (3-hydroxyeticyclidine) is an arylcyclohexylamine of the eticyclidine (PCE) family that produces dissociative, hallucinogenic, and euphoric effects and is presumed to act as an NMDA receptor antagonist. As with other 3-hydroxy arylcyclohexylamines, the phenolic substituent is associated with added opioid-receptor activity, which may contribute sedative properties on top of dissociation. Its metabolism has been characterized in human liver microsomes and authentic urine and hair samples, proceeding through N-dealkylation, deamination, oxidation, and glucuronidation, and paralleling that of the related designer ketamine O-PCE. In silico profiling of PCE and PCP analogs suggests moderate acute toxicity with cardiotoxicity signals, while robust human pharmacological data remain scarce.
both fingerprints on one instrument; where the marks line up the two compounds work the same lever, where a slot goes dark only one of them touches it. read straight from each entry's affinity table; nothing here is invented.
Agonist
Agonist
Antagonist
Antagonist
strengths are the entries' qualitative ratings (strong / moderate / weak); Ki and EC50 figures appear where an entry records them.